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STATE-OF-THE-ART REVIEW
Cardiac Lymphatic Vessels, Transport,
and Healing of the Infarcted Heart
Li-Hao Huang, PHD,a Kory J. Lavine, MD, PHD,b Gwendalyn J. Randolph, PHDa
SUMMARY
The lymphatic vasculature plays a key role in regulating tissue ﬂuid homeostasis, lipid transport, and immune surveillance
throughout the body. Although it has been appreciated that the heart relies on lymphatic vessels to maintain ﬂuid balance and
that such balance must be tightly maintained to allow for normal cardiac output, it has only recently come to light that the
lymphatic vasculature may serve as a therapeutic target with which to promote optimal healing following myocardial ischemia
and infarction. This article reviews the subject of cardiac lymphatic vessels and highlights studies that imply targeting of
lymphatic vessel development or transport using vascular endothelial growth factor-C therapy may serve as a promising
avenue for future clinical application in the context of ischemic injury. (J Am Coll Cardiol Basic Trans Science 2017;2:477–83)
© 2017 Washington University School of Medicine. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is anopenaccess articleunder theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
H ippocrates (460 to 370 BC) ﬁrst described thecolorless vessels that are now recognized ascomprising the lymphatic vasculature;
however, few studies focused on these specialized
vessels in the ensuing 2,000-year period (1). Histori-
cally, the reason why this research has evolved so
slowly is due to the technical difﬁculty in visualizing
the colorless lymphatic vasculature. In the early 20th
century, Florence Sabin injected ink into pig embryos
and discovered that lymphatic vessels originated
from out-sprouting of existing veins during develop-
ment (2). Not until the end of the 20th century, when
the lymphatic vasculature could be speciﬁcally visual-
ized through the discovery of key genes that faithfully
marked lymphatic endothelial cells, was it possible to
truly observe and appreciate lymphatic anatomy (3–
5). For this reason, the very presence of lymphatic ves-
sels in some anatomic locations is still being described.
For instance, in the central nervous system, lymphatic
vessels in the meningeal membranes around the brain
have only recently been discovered, where they func-
tion to facilitate immune cell and cerebral interstitial
ﬂuid drainage from the brain (6–9). In the eye, a
specialized structure referred to as Schlemm’s canal
bears features of lymphatic vessels and regulates
intraocular pressure (7,9,10). Novel functions of the
lymphatic vasculature have also recently emerged,
including a key role in preparing the developing lung
for inﬂation at birth to avoid respiratory neonatal fail-
ure (11). Progress has also been made in deﬁning a role
for lymphatic vessels in transporting cholesterol from
the artery wall to reduce risk of atherosclerosis. We
have recently reviewed this subject, but we will not
discuss it here (12).
Progress in lymphatic vessel research has also
emerged in the heart. This review focuses on the
current understanding of cardiac lymphatic biology.
First, we describe the origin of the cardiac lymphatic
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vasculature during development and then
review overall cardiac lymphatic anatomy
and function. Finally, we discuss the poten-
tial of therapeutic strategies to target cardiac
lymphatic vasculature.
ORIGIN OF THE SYSTEMIC
LYMPHATIC VASCULATURE
The lymphatic system includes lymphatic
vessels, lymph nodes, and lymphoid organs
(13). Different from the circulatory blood
vessels, lymphatic vessels are structurally
blind-ended at their distal segments. These
blind ends form vessels that are designed to absorb
interstitial ﬂuid and immune cells and are called
lymphatic capillaries. These vessels converge onto
deeper lymphatic structures called collecting vessels
that are equipped with valves and a muscular wall
that promotes transport rather than absorption. Flow
in the lymphatic vasculature as a whole is unidirec-
tional and is designed to drain extravascular ﬂuid,
macromolecules, and immune cells back into the
venous system to maintain interstitial ﬂuid balance.
The cells also transport absorbed lipids such as
chylomicron particles from the gut, and throughout
the body they function as a key structure in immune
surveillance (12,14). Despite much progress in all as-
pects of lymphatic vessel research, the organs from
which the lymphatic vascular system originate is still
under debate. As mentioned above, more than 100
years ago, lymphatic vessels were suggested to orig-
inate from lymph sacs by Florence Sabin (2). Sabin’s
early work was found consistent with results shown
later in mouse (15) and zebraﬁsh (16).
An alternative proposed by Huntington and
McClure (17) hypothesized that peripheral lymphatics
arose from a nonvenous source through lym-
phangioblasts that gave rise to lymph sacs, suggesting
that the origin of lymphatic vasculature is mixed. In
addition to the undisputed venous origin of many
lymphatic vessels, recent evidence also has emerged
to argue in favor of the concept that lymphatic
endothelial cells arise from other sources. In the
lumbar and dorsal dermal layer of mouse embryonic
skin, for example, approximately one-third of
lymphatic vessels are derived from nonvenous sour-
ces (18). In zebraﬁsh, lymphatic vessels indeed arise
from the cardinal vein but derive from a subset of
specialized angioblasts therein, where Wnt5b serves
to induce lymphatic speciﬁcation (19). Until recently,
little has been deﬁned regarding the origins of the
lymphatic vasculature during organogenesis. In the
last few years, however, work from different groups
agree on the derivation of at least part of the intes-
tinal lymphatic vasculature from nonvenous, local
sources. These origins depend upon the prior forma-
tion of arteries (20) and appear to descend from
hemogenic endothelium (21), a subset of endothelial
cells in blood vessels serving as a source for he-
matopoietic progenitors during a narrow develop-
mental window before liver and bone marrow become
the major hematopoietic tissues (22).
Only recently have data emerged regarding the
development and origins of lymphatic vasculature in
the heart (23). Lymphatic vessels emerge within the
developing heart at approximately embryonic day
12.5 (E12.5) and are ﬁrst visualized in association
with the ventral outﬂow tract. At E14.5,
LYVE1þPROX1þVEGFR3þ lymphatics sprout from the
sinus venosus and extend to cover the dorsal surface
of the left and right ventricles by E16.5. During late
gestation and early post-natal development, the
lymphatic vasculature expands to cover the entire
epicardial surface of heart (including dorsal and
ventral surfaces) and appears to mature by 2 weeks
of age. Beginning at E15.5, lymphatic vessels are
found in close proximity to developing coronary
veins and remain associated with venous vasculature
thereafter. Although interconnections between
lymphatic and venous endothelial cells are observed
at early time points, these connections are lost as the
lymphatic vasculature matures. Intriguingly, lineage
tracing studies using Tie2-Cre and Pdgfrb-CreERT2
mice (carrying markers of vascular endothelial cells)
revealed that cardiac lymphatics were derived from
a mixed pool of progenitors including venous and
putative hemogenic endothelial origins.
FLOW PATTERNS OF CARDIAC LYMPH
The cardiac lymphatic vasculature was ﬁrst described
in the 17th century by Rudbeck, discussed in Bradham
and Parker (24). Patek (25), publishing in 1939,
revealed that the mammalian cardiac lymphatic
vasculature invested all layers of the heart: the sub-
epicardium, the myocardium, and the sub-
endocardium. The ﬂow and composition of cardiac
lymph in dog were analyzed (26,27). That work
revealed that lymph ﬂow passed from the endocar-
dium, after interstitial ﬂuid entered lymphatic capil-
laries therein, to the epicardium where collecting
lymphatic vessels with activity capable of propelling
lymph ﬂow forward was observed (Figure 1A). Two
main collecting lymphatic vessels emerged, including
one that runs along the left conal vein toward the
left side of the pulmonary trunk and further upward
to the mediastinum to drain the right and left
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ventricles and the other, which can be seen on the
atrial surface, that runs along the left cardiac vein
(corresponding to the left marginal vein in humans),
coronary sinus, and the left atrium upward to the
mediastinum (Figure 1B) (25,28,29). Lymphatic
valves, operating similarly as venous valves, main-
tain lymph ﬂow unidirectionally, with the greatest
number of valves appearing in the subepicardial col-
lecting lymphatic vessels. The ventricles are invested
with more lymphatic vessels than the atria (25).
Lymphatic vessels appear in the cardiac valves,
potentially playing important roles. When cardiac
lymphatic drainage is impaired, the lymphatic capil-
lary network in the mitral valve appears increased
(30). Dogs and pigs have lymphatic vessels in both
atrioventricular valves, including tricuspid and mitral
valves, but humans have lymphatic vessels only in
the mitral valve (31).
FUNCTION OF CARDIAC LYMPHATIC VESSELS:
HISTORICAL AND NEW CONCEPTS
As delineated later, the concept that lymphatic
function is critical to maintain cardiac function has
been clear for some time. However, only recently has
the idea emerged that targeting the lymphatic
vasculature might provide therapeutic beneﬁt. Spe-
ciﬁcally, new evidence suggests that an expanded
lymphatic vasculature, brought about by lym-
phangiogenesis, and improved lymphatic function
augment tissue repair and prevent adverse
remodeling in the injured heart. We trace the devel-
opment of this area through its history.
Similar to other organs, the heart relies on cardiac
lymphatics to drain tissue ﬂuid in order to maintain
the steady-state interstitial ﬂuid equilibrium.
Myocardial contractions help to propel cardiac
lymphatic ﬂow. During diastole, when the heart
muscle relaxes, the ventricles ﬁll with blood, and
the resultant increase in chamber pressure drives
the ﬂow of lymph from the subendocardial to the
myocardial lymphatics. Subsequently, during systole,
ventricular contraction supplies the necessary force
to propel lymph from the myocardial to the sub-
epicardial lymphatics (32). If ﬂow rate becomes
reduced, increased myocardial interstitial edema,
which may contain necrotic products or toxins, oc-
curs, leading to increased interstitial pressure and to
compromised cardiac functions under both acute and
chronic conditions (33), due to increased ventricular
stiffness in diastole and reduced cardiac performance
(33,34). Indeed, a very small change in interstitial
pressure in the heart can have extreme effects on
cardiac output (33–35).
Osmotic forces are also at play in regulating ﬂuid
balance in the heart. Under normal conditions, the
protein concentration of interstitial ﬂuid (and lymph)
is much lower than that of plasma. This imbalance
creates a scenario that favors water movement back
into the bloodstream as it ﬂows toward higher protein
concentration. However, the impact of osmotic forces
is diminished by the fact that smaller proteins are
FIGURE 1 Cardiac Lymphatic Drainage of an Adult Mouse Heart
(A) Cross-section of a heart demonstrates the direction of cardiac lymph drainage from endocardium, myocardium to epicardium (ﬂow
indicated by arrows). (B) Two major collecting vessels (green) on the epicardium then assist to drain lymph, originally derived from the
endocardium, from apex to base: one collecting vessel (left) runs along the left conal vein upward to the pulmonary trunk and mediastinum;
the other vessel (right) runs along the left cardiac vein and passes the coronary sinus and left atrium upward to the mediastinum.
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more osmotically active than larger proteins and that
smaller proteins leak across inﬂamed vasculature,
resulting in increased interstitial protein concentra-
tion. As a consequence, osmotic forces that would
normally drive ﬂuid movement from the interstitial
space into lymphatics and eventually the venous
system are severely blunted and resultant tissue
edema ensues (36).
Cardiac surgery often produces damage to the
lymphatic vasculature that can lead to acute or occa-
sionally chronic edema (37). Thus, experiments have
been undertaken to describe the impact of surgical
lymphatic obstruction. Acute cardiac lymphatic
obstruction causes interstitial myocardial edema,
which in turn degrades ventricle performance, char-
acterized by decreased contractility and increased
diastolic stiffness (38,39). Chronic lymphatic vessel
blockade, surgically induced for experimental pur-
poses, leads to cardiac ﬁbrosis (40,41). Fibrosis in turn
increases interstitial resistance and compounds the
problem of ﬂuid ﬂow through the heart. This can be
due to collagen deposition (42) or possibly deposition
of other extracellular matrix components.
There are still many outstanding questions in the
ﬁeld to be answered, and it is a “black box” in un-
derstanding the detailed mechanisms of lymphatic
drainage through the heart. Are lymphatic capillaries
in the myocardium understood at the cellular level?
How do cardiac lymphatic capillaries take up ﬂuid
when pressures (>100 mm Hg) are generated every
second? Myocardial contractions help to propel car-
diac lymphatic ﬂow, but is the lymphatic ﬂow solely
dependent upon cardiac contraction? If not, how is
it regulated? Clearly, much remains to be learned,
and future investigation is needed to answer those
questions.
CONNECTIONS AMONG
INTERSTITIAL EDEMA, IMMUNE RESPONSES,
AND LYMPHANGIOGENESIS:
LESSONS LEARNED FROM THE SKIN
As indicated above, interstitial edema contributes
to tissue ﬁbrosis, which reinforces sluggish or rerou-
ted interstitial ﬂow. In skin, lymphedema and
accompanying ﬁbrosis are also associated with
elevated inﬁltrated immune cells including macro-
phages and lymphocytes (43–45). At least in some
scenarios, the inhibition of cyclooxygenase 2 reduces
the severity of lymphedema, suggesting the potential
role of inﬂammation in maintaining lymphedema
(46). Stimulation of lymphangiogenesis, again at least
in some settings, can act effectively to inhibit chronic
skin inﬂammation and immune cell accumulation
and increase lymphatic drainage (47,48). However,
whether lymphangiogenesis is necessary to support
additional lymph ﬂow, as is often assumed, is un-
clear, as a reasonable counterargument can be made
that the presence of lymphatic vessels at their basal
density is more than sufﬁcient to cover the physio-
logical and even pathological needs to cope with
problems of accumulated ﬂuid (13). In addition,
lymphangiogenesis combined with the formation of
tertiary lymphoid organs under certain circumstances
may sustain immune responses by facilitating the
transport of antigens as well as immune cells (13).
Inactivation of lymphatic vessel has been suggested
to serve as a novel therapy to reduce cardiac allograft
rejection and arteriosclerosis (49).
During the initial phase of edema after injury, M2
polarized macrophages, the major cell expressing
vascular endothelial growth factor (VEGF)-C (50),
regulate the formation of collateral lymphatic capil-
laries. By contrast, accumulation of CD4þ T cells
in the later stage inhibits lymphangiogenesis and
induces sclerosis of collecting lymphatics that leads
to interstitial ﬁbrosis and edema (51). Loss of CD4þ T
but not CD8þ T or CD25þ T cells decreases lymphe-
dema, inﬂammation and ﬁbrosis and increases
lymphangiogenesis (43), suggesting that lymphatic
growth is a highly coordinated process. Th2 T cells
and their cytokines interleukin (IL)-4 and IL-13
negatively regulate lymphangiogenesis and lym-
phatic function (52); anti-IL-4 and anti-IL-13
antibodies reduce lymphedema, suggesting the sig-
niﬁcant roles of Th2 T cells in the development of
interstitial ﬁbrosis (52,53). In contrast, excessive
generation of immature lymphatic vessels through
Th1 and Th17 CD4þ inﬂammatory T cells can drive
the pathogenesis of lymphedema (54). In sum, skin
lymphedema induces inﬂammation that includes
recruited immune cells that in turn potentially cause
the formation of ﬁbrotic tissues. Targeting lym-
phangiogenesis may be a therapy to repair the skin
lesions and possibly those in other organs. However,
in order for this approach to move forward, it is crit-
ical to understand the mechanisms by which lym-
phangiogenesis improves, but sometimes worsens,
edema and in particular to understand if the main
purpose of inﬂammatory lymphangiogenesis is to
promote ﬂuid or cell clearance.
MYOCARDIAL ISCHEMIA-INDUCED TISSUE
FIBROSIS CAUSED BY IMMUNE CELLS
AFFECTS LYMPHATIC DRAINAGE
Myocardial ischemia, the lack of blood supply to the
heart, causes rapid death of cardiac myocytes. At the
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same time, ﬂuid accumulates in the cardiac intersti-
tial space, leading to the formation of myocardial
edema due to increased myocardial microvascular
permeability and the ﬁltration rate exceeding the
lymph ﬂow rate (33,55). Similar to skin lymphedema,
myocardial edema can trigger cardiac ﬁbrosis (33,56)
as shown by increased collagen synthesis including
types I and III by ﬁbroblasts (57,58). In the infarct
zone, inﬂammatory signals recruit neutrophils within
1 day and, thereafter, monocyte/macrophages arrive.
During the ﬁrst 3 days post-injury, Ly-6Chi monocytes
inﬁltrate and scavenge necrotic debris, and when
resolution begins, they differentiate into Ly-6Clo
macrophages that promote healing (59,60). During
this process, cytokines are produced and promote the
activation of collagen-secreting ﬁbroblasts (61),
including secretion of anti-inﬂammatory cytokines
such as IL-10 (62) and IL-13 (63). Although resultant
ﬁbrotic tissue can compensate for the loss of car-
diomyocytes and provide structural support
following myocardial infarction to protect against
cardiac rupture, myocardial ﬁbrosis also has negative
consequences including hindering interstitial ﬂuid
drainage, impairing cardiac function, and contrib-
uting to adverse ventricular remodeling. Intriguingly,
lymphatic drainage through the myocardium can be
recovered by remodeling collateral circulation (64),
and this alleviates inﬂammatory responses orches-
trated by chemokines and recruited leukocytes eli-
cited following ischemic tissue injury (65).
Many concepts, including ﬂow and lymphangio-
genic response to inﬂammation, are borrowed from
the lesson learned from the skin. Although those
concepts may apply to the heart as well, they are also
likely to be organ-speciﬁc mechanisms. Clearly, there
will be many new connections to be discovered as we
explore the lymphatic ﬁeld in full.
LYMPHANGIOGENESIS AS A TARGET TO
PROMOTE HEART FUNCTION AFTER INJURY
After myocardial infarction, when much tissue is
destroyed, the restoration of even the basal density of
lymphatic vessels is needed to restore interstitial
ﬂow. The basal lymphangiogenic response is quite
robust in humans (66,67) and also in animals (23,68).
The increases in lymphatic density are sustained
during the healing phase, longer than that of blood
vessels (66). Perhaps there is a prolonged need for
lymphatic vessels during the healing phase, possibly
to drain excessive proteins and ﬂuid. When lym-
phatics fail to remove accumulated ﬂuid, expansion
of the interstitial ﬂuid compartment increases the
diffusion distance for oxygen, exacerbates the
hypoxic state, and increases the scale of infarct
development (69).
Given the role of VEGF-C in wound repair to induce
lymphangiogenesis, its use therapeutically beneﬁts
lymphedema (70). To investigate the inﬂuence of
lymphangiogenesis on cardiac function, VEGF-C
therapy was applied after myocardial infarction and
found to improve cardiac function post-myocardial
infarction while limiting ﬁbrosis and lingering
inﬂammation (23,68). Although 1 of these 2 studies
pointed solely to the impact of VEGF-C on increasing
local lymphangiogenesis, Henri et al. (68) observed
that local lymphangiogenesis was quite robust in the
untreated cohort but that nonetheless VEGF-C ther-
apy was beneﬁcial. The study went on to ﬁnd that
lymphatic capillary remodeling was far from the
whole story, that indeed the major issue appeared to
be adverse remodeling of the collecting lymphatics
CENTRAL ILLUSTRATION VEGF-C Treatment After Injury
Promotes Heart Function
Huang, L.-H. et al. J Am Coll Cardiol Basic Trans Science. 2017;2(4):477–83.
Increased lymphangiogenesis of lymphatic capillaries and pre-collecting and collecting
vessels remodeling after treating the infarct heart with VEGF-C improves cardiac
functions in the infarcted heart. VEGF ¼ vascular endothelial growth factor.
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that negatively impacted ﬂuid transport from
infarcted and adjacent uninfarcted areas (68). Thus, it
is possible that, although lymphangiogenesis of the
small, blind-ended lymphatic capillaries garners
attention most readily because this change is most
obvious (23), the most relevant therapeutic target
may be sustaining function of the deeper collecting
lymphatic vessels (68). Collectively, these 2 studies
raise a promising new approach to restoring the heart
after myocardial infarction and highlight the poten-
tial that additional work on the lymphatic vasculature
in the cardiac system may yield in treating dysfunc-
tion of the heart (Central Illustration).
CONCLUSIONS
Although the lymphatic vasculature in the heart
has been studied for some time, recent studies in the
ﬁeld have introduced for the ﬁrst time the possibility
that heart conditions such as ischemia and infarc-
tion may be treated by direct targeting of the
lymphatic vasculature. In particular, the therapeutic
administration of VEGF-C in 2 different studies
improved the rate and quality of cardiac healing in
experimental myocardial infarction in mice and rats.
The positive outcome may be attributed to increased
lymphangiogenesis of lymphatic capillaries in the
heart but may otherwise also relate to sustained
functionality of the deeper lymphatic collecting ves-
sels. There is much work to be done in considering
lymphatic transport as a means to combat adverse
events in the heart. The lymphatic vessels of the heart
deserve increased attention.
ADDRESS FOR CORRESPONDENCE: Dr. Li-Hao
Huang, Department of Pathology and Immunology,
Washington University School of Medicine, 425 South
Euclid Avenue, BJCIH 8307, St. Louis, Missouri 63110.
E-mail: paul.huang@wustl.edu. OR Dr. Gwendalyn J.
Randolph, Department of Pathology and Immunology,
Washington University School of Medicine, 425 South
Euclid Avenue, BJCIH 8307, St. Louis, Missouri 63110.
E-mail: gjrandolph@wuslt.edu.
RE F E RENCE S
1. Lord RS. The white veins: conceptual difﬁculties
in the history of the lymphatics. Med Hist 1968;12:
174–84.
2. Sabin FR. On the origin of the lymphatic system
from the veins and the development of the lymph
hearts and thoracic duct in the pig. American
Journal of Anatomy 1902;1:367–89.
3. Wigle JT, Oliver G. Prox1 function is required for
the development of the murine lymphatic system.
Cell 1999;98:769–78.
4. Breiteneder-Geleff S, Soleiman A, Kowalski H,
et al. Angiosarcomas express mixed endothelial
phenotypes of blood and lymphatic capillaries:
podoplanin as a speciﬁc marker for lymphatic
endothelium. Am J Pathol 1999;154:385–94.
5. Banerji S, Ni J, Wang S-X, et al. LYVE-1, a new
homologue of the CD44 glycoprotein, is a lymph-
speciﬁc receptor for hyaluronan. J Cell Biol 1999;
144:789–801.
6. Aspelund A, Antila S, Proulx ST, et al. A dural
lymphatic vascular system that drains brain inter-
stitial ﬂuid and macromolecules. J Exp Med 2015;
212:991–9.
7. Park D-Y, Lee J, Park I, et al. Lymphatic regu-
lator PROX1 determines Schlemm’s canal integrity
and identity. J Clin Invest 2014;124:3960–74.
8. Kizhatil K, Ryan M, Marchant JK, Henrich S,
John SW. Schlemm’s canal is a unique vessel with a
combination of blood vascular and lymphatic
phenotypes that forms by a novel developmental
process. PLoS Biol 2014;12:e1001912.
9. Thomson BR, Heinen S, Jeansson M, et al.
A lymphatic defect causes ocular hypertension
and glaucoma in mice. J Clin Invest 2014;124:
4320–4.
10. Aspelund A, Tammela T, Antila S, et al. The
Schlemm’s canal is a VEGF-C/VEGFR-3–responsive
lymphatic-like vessel. J Clin Invest 2014;124:
3975–86.
11. Jakus Z, Gleghorn JP, Enis DR, et al. Lymphatic
function is required prenatally for lung inﬂation at
birth. J Exp Med 2014;211:815–26.
12. Huang L-H, Elvington A, Randolph GJ. The role
of the lymphatic system in cholesterol transport.
Front Pharmacol 2015;6:182.
13. Randolph GJ, Ivanov S, Zinselmeyer BH,
Scallan JP. The lymphatic system: integral roles in
immunity. Annu Rev Immunol 2017;35:31–52.
14. Randolph GJ, Miller NE. Lymphatic transport
of high-density lipoproteins and chylomicrons.
J Clin Invest 2014;124:929–35.
15. Srinivasan RS, Dillard ME, Lagutin OV, et al.
Lineage tracing demonstrates the venous origin of
the mammalian lymphatic vasculature. Genes Dev
2007;21:2422–32.
16. Yaniv K, Isogai S, Castranova D, Dye L,
Hitomi J, Weinstein BM. Live imaging of lymphatic
development in the zebraﬁsh. Nat Med 2006;12:
711–6.
17. Huntington GS, McClure CF. The anatomy and
development of the jugular lymph sacs in the
domestic cat (Felis domestica). Am J Anat 1910;
10:177–312.
18. Martinez-Corral I, Ulvmar MH, Stanczuk L,
et al. Nonvenous origin of dermal lymphatic
vasculature. Circ Res 2015;116:1649–54.
19. Nicenboim J, Malkinson G, Lupo T, et al.
Lymphatic vessels arise from specialized angio-
blasts within a venous niche. Nature 2015;522:
56–61.
20. Mahadevan A, Welsh Ian C, Sivakumar A, et al.
The left-right Pitx2 pathway drives organ-speciﬁc
arterial and lymphatic development in the intes-
tine. Dev Cell 2014;31:690–706.
21. Stanczuk L, Martinez-Corral I, Ulvmar MH, et al.
cKit Lineage hemogenic endothelium-derived cells
contribute to mesenteric lymphatic vessels. Cell
Rep 2015;10:1708–21.
22. Lancrin C, Sroczynska P, Stephenson C,
Allen T, Kouskoff V, Lacaud G. The haemangio-
blast generates haematopoietic cells through a
haemogenic endothelium stage. Nature 2009;457:
892–5.
23. Klotz L, Norman S, Vieira JM, et al. Cardiac
lymphatics are heterogeneous in origin and
respond to injury. Nature 2015;522:62–7.
24. Bradham RR, Parker EF. The cardiac lym-
phatics. Ann Thorac Surg 1973;15:526–35.
25. Patek PR. The morphology of the lymphactics
of the mammalian heart. Am J Anat 1939;64:
203–49.
26. Drinker CK, Warren MF, Maurer FW,
McCarrell JD. The ﬂow, pressure, and composition
of cardiac lymph. Am J Physiol-Legacy Content
1940;130:43–55.
27. Miller AJ, Ellis A, Katz LN. Cardiac lymph: ﬂow
rates and composition in dogs. Am J Physiol-
Legacy Content 1964;206:63–6.
28. Flaht-Zabost A, Gula G, Ciszek B, et al. Cardiac
mouse lymphatics: developmental and anatomical
update. Anat Rec (Hoboken) 2014;297:1115–30.
29. Ratajska A, Gula G, Flaht-Zabost A, et al.
Comparative and developmental anatomy of car-
diac lymphatics. ScientiﬁcWorldJournal 2014;
2014:183170.
Huang et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 4 , 2 0 1 7
Heart Lymphatics Impact Myocardial Infarction A U G U S T 2 0 1 7 : 4 7 7 – 8 3
482
30. Miller AJ, Pick R, Katz LN. Lymphatics of the
mitral valve of the dog demonstration and dis-
cussion of the possible signiﬁcance. Circ Res 1961;
9:1005–9.
31. Johnson RA, Blake TM. Lymphatics of the
heart. Circulation 1966;33:137–42.
32. Cui Y. Impact of lymphatic vessels on the
Heart. Thorac Cardiovasc Surg 2010;58:1–7.
33. Laine G, Allen S. Left ventricular myocardial
edema. Lymph ﬂow, interstitial ﬁbrosis, and car-
diac function. Circ Res 1991;68:1713–21.
34. Pogatsa G, Dubecz E, Gabor G. The role of
myocardial edema in the left ventricular diastolic
stiffness. Basic Res Cardiol 1976;71:263–9.
35. Dongaonkar RM, Stewart RH, Geissler HJ,
Laine GA. Myocardial microvascular permeability,
interstitial edema, and compromised cardiac
function. Cardiovasc Res 2010;11:145.
36. Stewart RH, Rohn DA, Mehlhorn U, Davis KL,
Allen SJ, Laine GA. Regulation of microvascular
ﬁltration in the myocardium by interstitial ﬂuid
pressure. Am J Physiol Regul Integr Comp Physiol
1996;271:R1465–9.
37. Mehlhorn U, Geissler HJ, Laine GA, Allen SJ.
Myocardial ﬂuid balance. Eur J Cardiothorac Surg
2001;20:1220–30.
38. Ludwig LL, Schertel ER, Pratt JW, et al.
Impairment of left ventricular function by acute
cardiac lymphatic obstruction. Cardiovasc Res
1997;33:164–71.
39. Sun S, Lie J. Cardiac lymphatic obstruction:
ultrastructure of acute-phase myocardial injury in
dogs. Mayo Clinic Proc 1977:785–92.
40. Miller AJ, Pick R, Katz LN, Jones C, Rodgers J.
Ventricular endomyocardial changes after impair-
ment of cardiac lymph ﬂow in dogs. Brit Heart J
1963;25:182.
41. Kluge T, Ullal SR. Pathology of the heart
following chronic cardiac lymphatic obstruction.
Acta Pathologica Microbiologica Scandinavica
Section A Pathology 1972;80:150–8.
42. Stewart RH, Geissler HJ, Allen SJ, Laine GA.
Protein washdown as a defense mechanism
against myocardial edema. Am J Physiol Heart Circ
Physiol 2000;279:H1864–8.
43. Zampell JC, Yan A, Elhadad S, Avraham T,
Weitman E, Mehrara BJ. CD4þ cells regulate
ﬁbrosis and lymphangiogenesis in response to
lymphatic ﬂuid stasis. PLoS One 2012;7:e49940.
44. Rockson SG. Lymphedema. Am J Med 2001;
110:288–95.
45. Gousopoulos E, Proulx ST, Scholl J, Uecker M,
Detmar M. Prominent lymphatic vessel hyperplasia
with progressive dysfunction and distinct immune
cell inﬁltration in lymphedema. Am J Pathol 2016;
186:2193–203.
46. Kashiwagi S, Hosono K, Suzuki T, Takeda A,
Uchinuma E, Majima M. Role of COX-2 in lym-
phangiogenesis and restoration of lymphatic ﬂow
in secondary lymphedema. Lab Invest 2011;91:
1314–25.
47. Huggenberger R, Ullmann S, Proulx ST,
Pytowski B, Alitalo K, Detmar M. Stimulation of
lymphangiogenesis via VEGFR-3 inhibits chronic
skin inﬂammation. J Exp Med 2010;207:2255–69.
48. Kim H, Kataru RP, Koh GY. Inﬂammation-
associated lymphangiogenesis: a double-edged
sword? J Clin Invest 2014;124:936–42.
49. Nykänen AI, Sandelin H, Krebs R, et al. Tar-
geting lymphatic vessel activation and CCL21
production by vascular endothelial growth factor
receptor-3 inhibition has novel immunomodula-
tory and antiarteriosclerotic effects in cardiac al-
lografts. Circulation 2010;121:1413–22.
50. Ghanta S, Cuzzone DA, Torrisi JS, et al.
Regulation of inﬂammation and ﬁbrosis by mac-
rophages in lymphedema. Am J Physiol Heart Circ
Physiol 2015;308:H1065–77.
51. Gardenier JC, Hespe GE, Kataru RP, et al.
Diphtheria toxin-mediated ablation of lymphatic
endothelial cells results in progressive lymphe-
dema. JCI Insight 2016;1:e84095.
52. Shin K, Kataru RP, Park HJ, et al. TH2 cells and
their cytokines regulate formation and function of
lymphatic vessels. Nat Comm 2015;6:6196.
53. Avraham T, Zampell JC, Yan A, et al. Th2 dif-
ferentiation is necessary for soft tissue ﬁbrosis and
lymphatic dysfunction resulting from lymphe-
dema. FASEB J 2013;27:1114–26.
54. Ogata F, Fujiu K, Matsumoto S, et al. Excess
lymphangiogenesis cooperatively induced by
macrophages and CD4þ T cells drives the patho-
genesis of lymphedema. J Invest Dermatol 2016;
136:706–14.
55. Mehlhorn U, Davis KL, Laine GA, Geissler HJ,
Allen SJ. Myocardial ﬂuid balance in acute hyper-
tension. Microcirculation 1996;3:371–8.
56. Laine GA, Granger HJ. Microvascular, intersti-
tial, and lymphatic interactions in normal heart.
Am J Physiol Heart Circ Physiol 1985;249:
H834–42.
57. Davis K, Laine G, Geissler H, Mehlhorn U,
Brennan M, Allen S. Effects of myocardial edema
on the development of myocardial interstitial
ﬁbrosis. Microcirculation 2000;7:269–80.
58. Kong D, Kong X, Wang L. Effect of cardiac
lymph ﬂow obstruction on cardiac collagen syn-
thesis and interstitial ﬁbrosis. Physiol Res 2006;
55:253.
59. Hilgendorf I, Gerhardt LM, Tan TC, et al.
Ly-6Chigh monocytes depend on Nr4a1 to
balance both inﬂammatory and reparative
phases in the infarcted myocardium. Circ Res
2014;114:1611–22.
60. Epelman S, Lavine KJ, Beaudin AE, et al. Em-
bryonic and adult-derived resident cardiac mac-
rophages are maintained through distinct
mechanisms at steady state and during inﬂam-
mation. Immunity 2014;40:91–104.
61. Hofmann U, Beyersdorf N, Weirather J, et al.
Activation of CD4þ T lymphocytes improves
wound healing and survival after experimental
myocardial infarction in mice. Circulation 2012;
125:1652–63.
62. Dobaczewski M, Xia Y, Bujak M, Gonzalez-
Quesada C, Frangogiannis NG. CCR5 signaling
suppresses inﬂammation and reduces adverse
remodeling of the infarcted heart, mediating
recruitment of regulatory T cells. Am J Pathol
2010;176:2177–87.
63. Wynn T. Cellular and molecular mechanisms of
ﬁbrosis. J Pathol 2008;214:199–210.
64. Santos AC, de Lima JJP, Botelho MF, et al.
Cardiac lymphatic dynamics after ischemia and
reperfusion—experimental model. Nucl Med Biol
1998;25:685–8.
65. Frangogiannis NG. Chemokines in ischemia
and reperfusion. Thromb Haemost 2007;97:738.
66. Ishikawa Y, Akishima-Fukasawa Y, Ito K, et al.
Lymphangiogenesis in myocardial remodelling af-
ter infarction. Histopathology 2007;51:345–53.
67. Nakamura K, Rockson SG. The role of the
lymphatic circulation in the natural history and
expression of cardiovascular disease. Int J Cardiol
2008;129:309–17.
68. Henri O, Pouehe C, Houssari M, et al. Selective
stimulation of cardiac lymphangiogenesis reduces
myocardial edema and ﬁbrosis leading to
improved cardiac function following myocardial
infarction. Circulation 2016;133:1484–97.
69. Dellsperger KC, Clothier JL, Hartnett JA,
Haun LM, Marcus ML. Acceleration of the wave-
front of myocardial necrosis by chronic hyperten-
sion and left ventricular hypertrophy in dogs. Circ
Res 1988;63:87–96.
70. Szuba A, Skobe M, Karkkainen MJ, et al.
Therapeutic lymphangiogenesis with human
recombinant VEGF-C. FASEB J 2002;16:1985–7.
KEY WORDS cardiac lymphatic vessels,
immune responses, interstitial edema,
lymphangiogenesis, myocardial infarction,
tissue ﬁbrosis, vascular endothelial growth
factor-C
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 4 , 2 0 1 7 Huang et al.
A U G U S T 2 0 1 7 : 4 7 7 – 8 3 Heart Lymphatics Impact Myocardial Infarction
483
